Clinical Trial News

Bank of America Securities' Sachin Jain maintains Buy rating on AstraZeneca (AZN) with a £14,500.00 price target, citing positive biomarker data from datopotamab TL01 study in second-line lung cancer and potential catalysts like AVANZAR phase III trial in 2025.

Ruxolitinib shows efficacy in refractory sclerotic chronic graft vs host disease (cGVHD), with 49% partial response at 6 months and 77% ongoing response at 12 months, though 20.8% treatment failure rate and 2.2% nonrelapse mortality observed.

Bambusa Therapeutics Inc. secures $15 million in Series Seed funding to develop bispecific antibodies for immunology and inflammation disorders, aiming to advance its pipeline to Phase I clinical studies.

Actuate Therapeutics reports elraglusib shows anti-tumor activity with 2 durable complete responses and ~62% disease control rate in 8 relapsed/refractory Ewing and Ewing-related sarcoma patients. Enrollment continues with topline data expected in 1H 2025.

Jazz Pharmaceuticals to present five abstracts at ESMO Congress 2024, including new data on zanidatamab for HER2-positive mGEA and mCRC, and Zepzelca for relapsed SCLC.

FDA reports 4 ASF and 3 avian flu vaccine manufacturers from Thailand, US, and Vietnam undergoing trials. Only AVAC ASF vaccine from Vietnam approved for limited rollout. DA allocated P350 million for 600,000 doses, starting in Lobo, Batangas. DA aims to expand ASF vaccine rollout to other Luzon areas and red zones in Visayas and Mindanao.

Candid Therapeutics, a biotech startup, launched with $370 million to develop T-cell engager drugs for inflammatory diseases, acquiring rights to two cancer drug prospects from Vignette Bio and TRC 2004. CEO Ken Song believes T-cell engagers are a better solution for autoimmune diseases than cell therapy due to lower production costs and easier administration. The company plans to start clinical trials for autoimmune conditions next year.

Biologics by McKesson selected by Geron Corp. as a specialty pharmacy provider for RYTELO™ (imetelstat), a telomerase inhibitor for treating low- to intermediate-1 risk myelodysplastic syndromes (MDS) with transfusion-dependent anemia. RYTELO, approved by the FDA on June 6, 2024, inhibits telomerase activity, preventing telomere binding. Biologics by McKesson is committed to providing innovative, high-touch care for patients.

T2 Biosystems updates on direct-from-blood diagnostic tests for antimicrobial resistance, pediatric Candida infections, Lyme disease, and Candida auris. Key plans include finalizing a 510(k) for the T2Resistance® Panel by Q4 2024, pending FDA clearance for the T2Candida® Panel for pediatric use, and submitting a 510(k) for the T2Bacteria® Panel for pediatric bacterial infections. The company also decides to build or buy a lab for the T2Lyme™ Panel and seeks non-dilutive funding for a Candida auris test. Three pipeline products have received FDA Breakthrough Device designation, with multiple new product launches expected in 2024-2025.

Akeso's stock surged after announcing promising lung cancer treatment results, outperforming Merck's Keytruda in a phase III trial. Ivonescimab showed increased progression-free survival and is pending approval in China, with potential for significant commercial success.